ERK-dependent protein phosphorylation in KRAS-mutant cancer: a mix of the expected and surprising

Kevin Huang; Yubao Wang; Thomas M Roberts

doi:10.1016/j.tibs.2024.10.011

ERK-dependent protein phosphorylation in KRAS-mutant cancer: a mix of the expected and surprising

Trends Biochem Sci. 2024 Nov 16:S0968-0004(24)00249-4. doi: 10.1016/j.tibs.2024.10.011. Online ahead of print.

Authors

Kevin Huang¹, Yubao Wang², Thomas M Roberts³

Affiliations

¹ Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
² Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. Electronic address: [email protected].
³ Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. Electronic address: [email protected].

PMID: 39551665
DOI: 10.1016/j.tibs.2024.10.011

Abstract

Recently developed KRAS inhibitors have delivered clinical benefits but their antitumor efficacy remains limited. A recent study by Klomp et al. reports an unprecedentedly comprehensive profiling of protein phosphorylation dependent on the KRAS pathway and generates new insights and directions to improve the efficacy of KRAS-targeted therapies.

Keywords: ERK; KRAS; MEK; phosphorylation.